Accueil   Diary - News   All news VALBIOTIS will present the results of the international Phase IIA clinical study of VALEDIA® before 31 July 2019

VALBIOTIS will present the results of the international Phase IIA clinical study of VALEDIA® before 31 July 2019

  • The results of this study will evaluate the efficacy of VALEDIA® in prediabetic subjects for the first time
  • Predicted to be the catalyst for concluding a commercial partnership with a major player in the healthcare sector
  • Beyond prediabetes, additional results are expected to shed light on the potential development of other applications of VALEDIA®

 

La Rochelle, 14 May 2019 (5:40 pm CEST) – VALBIOTIS FR0013254851 – ALVAL / PEA/SME eligible), a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the completion of the international Phase IIA clinical study evaluating VALEDIA® in prediabetic subjects, after the final follow-up visit was conducted with the last patient. VALBIOTIS will present the results of this study before 31 July 2019.

 

Read the press release